Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
2 files | 1.87 MB
Add to list
  1. Search results
  2. Associations of the gut microbiome wi...

Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial

Emiel De Jaeghere (UGent) , Hannelore Hamerlinck (UGent) , Sandra Tuyaerts, Lien Lippens (UGent) , An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, et al.
(2024) GYNECOLOGIC ONCOLOGY. 191. p.275-286
Author
Organization
Project
Keywords
Immune checkpoint inhibition, Cervical cancer, Endometrial cancer, Gut metagenome, Gut microbiome, IMMUNOTHERAPY, RESISTANCE, CARCINOMA, EFFICACY

Downloads

  • Download
    Denys Manuscript Unmarked REV.docx
    • full text (Accepted manuscript)
    • |
    • open access
    • |
    • Word
    • |
    • 214.89 KB
  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 1.66 MB

Citation

Please use this url to cite or link to this publication:

MLA
De Jaeghere, Emiel, et al. “Associations of the Gut Microbiome with Outcomes in Cervical and Endometrial Cancer Patients Treated with Pembrolizumab : Insights from the Phase II PRIMMO Trial.” GYNECOLOGIC ONCOLOGY, vol. 191, 2024, pp. 275–86, doi:10.1016/j.ygyno.2024.10.020.
APA
De Jaeghere, E., Hamerlinck, H., Tuyaerts, S., Lippens, L., Van Nuffel, A. M. T., Baiden-Amissah, R., … Denys, H. (2024). Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial. GYNECOLOGIC ONCOLOGY, 191, 275–286. https://doi.org/10.1016/j.ygyno.2024.10.020
Chicago author-date
De Jaeghere, Emiel, Hannelore Hamerlinck, Sandra Tuyaerts, Lien Lippens, An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, et al. 2024. “Associations of the Gut Microbiome with Outcomes in Cervical and Endometrial Cancer Patients Treated with Pembrolizumab : Insights from the Phase II PRIMMO Trial.” GYNECOLOGIC ONCOLOGY 191: 275–86. https://doi.org/10.1016/j.ygyno.2024.10.020.
Chicago author-date (all authors)
De Jaeghere, Emiel, Hannelore Hamerlinck, Sandra Tuyaerts, Lien Lippens, An M.T. Van Nuffel, Regina Baiden-Amissah, Peter Vuylsteke, Stéphanie Henry, Xuan Bich Trinh, Peter A. van Dam, Sandrine Aspeslagh, Alex De Caluwé, Eline Naert, Diether Lambrechts, An Hendrix, Olivier De Wever, Koen Van de Vijver, Frédéric Amant, Katrien Vandecasteele, Bruno Verhasselt, and Hannelore Denys. 2024. “Associations of the Gut Microbiome with Outcomes in Cervical and Endometrial Cancer Patients Treated with Pembrolizumab : Insights from the Phase II PRIMMO Trial.” GYNECOLOGIC ONCOLOGY 191: 275–286. doi:10.1016/j.ygyno.2024.10.020.
Vancouver
1.
De Jaeghere E, Hamerlinck H, Tuyaerts S, Lippens L, Van Nuffel AMT, Baiden-Amissah R, et al. Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial. GYNECOLOGIC ONCOLOGY. 2024;191:275–86.
IEEE
[1]
E. De Jaeghere et al., “Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial,” GYNECOLOGIC ONCOLOGY, vol. 191, pp. 275–286, 2024.
@article{01JDYX0Y1V6VYSRBVCAZHKYAD8,
  author       = {{De Jaeghere, Emiel and Hamerlinck, Hannelore and Tuyaerts, Sandra and Lippens, Lien and Van Nuffel, An M.T. and Baiden-Amissah, Regina and Vuylsteke, Peter and Henry, Stéphanie and Trinh, Xuan Bich and van Dam, Peter A. and Aspeslagh, Sandrine and De Caluwé, Alex and Naert, Eline and Lambrechts, Diether and Hendrix, An and De Wever, Olivier and Van de Vijver, Koen and Amant, Frédéric and Vandecasteele, Katrien and Verhasselt, Bruno and Denys, Hannelore}},
  issn         = {{0090-8258}},
  journal      = {{GYNECOLOGIC ONCOLOGY}},
  keywords     = {{Immune checkpoint inhibition,Cervical cancer,Endometrial cancer,Gut metagenome,Gut microbiome,IMMUNOTHERAPY,RESISTANCE,CARCINOMA,EFFICACY}},
  language     = {{eng}},
  pages        = {{275--286}},
  title        = {{Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab : insights from the phase II PRIMMO trial}},
  url          = {{http://doi.org/10.1016/j.ygyno.2024.10.020}},
  volume       = {{191}},
  year         = {{2024}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: